|
SBNO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.4548809086109E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.25429996891791E-09 |
| Normal-vs-Stage2 |
1.438480E-04 |
| Normal-vs-Stage3 |
6.96553925649823E-13 |
| Normal-vs-Stage4 |
3.73410191656376E-11 |
| Stage1-vs-Stage2 |
3.559000E-01 |
| Stage1-vs-Stage3 |
8.975600E-02 |
| Stage1-vs-Stage4 |
2.750400E-02 |
| Stage2-vs-Stage3 |
5.706400E-02 |
| Stage2-vs-Stage4 |
2.316300E-02 |
| Stage3-vs-Stage4 |
5.215800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.71549457867104E-11 |
| Normal-vs-AfricanAmerican |
1.979160E-04 |
| Normal-vs-Asian |
4.05040000428514E-08 |
| Caucasian-vs-AfricanAmerican |
5.320000E-01 |
| Caucasian-vs-Asian |
8.104200E-01 |
| AfricanAmerican-vs-Asian |
4.093000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.81945602817768E-12 |
| Normal-vs-Female |
1.12249987083146E-10 |
| Male-vs-Female |
2.485400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.8922996503079E-10 |
| Normal-vs-Age(41-60Yrs) |
3.54740004038234E-09 |
| Normal-vs-Age(61-80Yrs) |
2.9772995180366E-10 |
| Normal-vs-Age(81-100Yrs) |
3.002400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.221400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.714200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.047800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.645200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.664000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.146200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.098300E-02 |
| Classical-VS-Follicular |
6.740400E-01 |
| Classical-VS-Other |
2.126400E-01 |
| Classical-VS-Normal |
3.72246677926569E-12 |
| Tall-VS-Follicular |
7.586400E-02 |
| Tall-VS-Other |
6.282200E-01 |
| Tall-VS-Normal |
9.47519951388642E-10 |
| Follicular-VS-Other |
9.145500E-02 |
| Follicular-VS-Normal |
1.81971999999586E-05 |
| Other-VS-Normal |
5.983600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.73340255879862E-11 |
| Normal-vs-N1 |
8.09059486073238E-11 |
| N0-vs-N1 |
8.531600E-02 |
|
|
